Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache

Current Medical Research and Opinion

Volumn 15, Issue 4, 1999, Pages 282-289

  Mauskop, Alexander ^a   Farkkila, Markus ^b   Hering Hanit, Rachel ^c   Rapoport, Alan ^e   Warner, John ^d  

^a New York Headache Center   (United States)

^b UNIVERSITY OF HELSINKI   (Finland)

^c MEIR MEDICAL CENTER   (Israel)

^d VANDERBILT UNIVERSITY   (United States)

^e NONE

Author keywords

Migraine; Zolmitriptan

Indexed keywords

ANTIMIGRAINE AGENT; ZOLMITRIPTAN;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHENIA; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SCHOOL CHILD; THORAX PAIN; ULCERATIVE COLITIS; VERTIGO;

EID: 0033404964     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999909116498     Document Type: Article

References (11)

1. 1B/1D agonist: an overview of efficacy. Cephalalgia, 17 (Suppl 18), 28-40.
2. Rapoport, A. M., Ramadan, N. M., Adelman, J. U., Mathew, N. T., Elkind, A. H., Kudrow, D. B. and Earl, N. L. (1997). Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology, 49, 1210-1218.
3. Solomon, G. D., Cady, R. K., Klapper, J. A., Earl, N. L., Saper, J. R. and Ramadan, N. M. (1997). Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology, 49, 1219-1225.
4. Tepper, S., Donnan, G. A., Dowson, A. J., Bomhol, M. A. M., Elkind, A., Meloche, J., Fletcher, P. E. and Millson, D.S. (1999). A long-term study to maximize migraine relief with Zolmitriptan. Curr. Med. Res. Opin., 15(4) 254-271.
5. Headache Classification Committee of the International Headache Society. (1988). Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia, 8 (Suppl 7), 1-96.
6. Visser, W. H., Jaspers, N. M., de Vriend, R. H. and Ferrari, M. D. (1996). Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia, 16, 554-559.
7. 1D) agonists and other agents in acute migraine. Neurol. Clin., 15(1), 61-83.
8. International 311C90 Long-Term Study Group (1998). The long-term tolerability and efficacy of oral zolmitriptan (Zomig™, 311C90) in the acute treatment of migraine. An international study. Headache, 38, 173-183.
9. IB/ID agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia, 17 (Suppl 18), 41-52.
10. Pfaffenrath, V., Cunin, G., Sjonell, G. and Prendergast, S. (1998). Efficacy and safety of sumatriptan tablets (25 mg, 50 mg and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache, 38, 184-190.
11. Cull, R. E., Price, W. H. and Dunbar, A. (1997). The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. J. Neurol. Neurosurg. Psychiatry, 62, 490-495.